Amphastar Pharmaceuticals, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Amphastar Pharmaceuticals, Inc. (AMPH) had Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued of $1.40 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued · last filed 2026-02-26
- 2025-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $1.40M.
- 2024-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $1.30M.
- 2023-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $1.00M.
- 2022-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $800.00K.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued |
|---|---|
| 2025-12-31 | $1.40M 10-K · filed 2026-02-26 |
| 2024-12-31 | $1.30M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $800.00K 10-K · filed 2025-03-03 |
| 2021-12-31 | $500.00K 10-K · filed 2024-02-29 |
| 2020-12-31 | $200.00K 10-K · filed 2023-03-01 |
| 2019-12-31 | $300.00K 10-K · filed 2022-03-11 |
| 2018-12-31 | $100.00K 10-K · filed 2021-03-15 |
| 2017-12-31 | $100.00K 10-K · filed 2019-03-15 |
| 2016-12-31 | $300.00K 10-K · filed 2018-03-14 |
| 2015-12-31 | $100.00K 10-K · filed 2017-03-15 |
| 2014-12-31 | $4.30M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |